Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-1.78%
$42.72
0% positive prob.
5-Day Prediction
-2.19%
$42.55
0% positive prob.
20-Day Prediction
-2.34%
$42.48
0% positive prob.
SEC 8-K filings with transcript text
Feb 24, 2026 · 100% conf.
1D
-1.78%
$42.72
Act: -1.70%
5D
-2.19%
$42.55
Act: +4.30%
20D
-2.34%
$42.48
Kiniksa Pharmaceuticals International, plc_February 24, 2026 0001730430false00017304302026-02-242026-02-24
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)
England and Wales 001-730430 98-1795578
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
Kiniksa Pharmaceuticals International, plc 105 Piccadilly, Second Floor London, W1J 7NJ England, United Kingdom (781) 431-9100 (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA, 02421 (781) 431-9100 (Address, zip code and telephone number, including area code of agent for service) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Ordinary Shares $0.000273235 nominal value
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On February 24, 2026, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the fiscal year ended December 31, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Kiniksa Pharmaceuticals International, plc, dated February 24, 2026
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 24, 2026 By: /s/ Douglas Barry
Douglas Barry
Senior Vice President, Chief Legal Officer and Secretary
Jan 12, 2026 · 100% conf.
1D
-1.78%
$42.72
Act: -1.70%
5D
-2.19%
$42.55
Act: +4.30%
20D
-2.34%
$42.48
Kiniksa Pharmaceuticals International, plc_January 12, 2026 0001730430false00017304302026-01-122026-01-12
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)
England and Wales 001-730430 98-1795578
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
105 Piccadilly, Second Floor London, W1J 7NJ England, United Kingdom (781) 431-9100 (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA, 02421 (781) 431-9100 (Address, zip code and telephone number, including area code of agent for service) 23 Old Bond Street, Floor 3 London, W1S 4PZ England, United Kingdom (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Ordinary Shares $0.000273235 nominal value
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On January 12, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) issued a press release announcing, among other things, that (i) ARCALYST net product revenue was $677.5 million for the full year 2025 (unaudited), (ii) gross-to-net was 8.4% for the full year 2025 (unaudited) and (iii) as of December 31, 2025 it had $414.1 million of cash, cash equivalents and short-term investments and no debt (unaudited). A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Kiniksa Pharmaceuticals International, plc, dated January 12, 2026
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 12, 2026 By: /s/ Douglas Barry
Douglas Barry
Senior Vice President, Chief Legal Officer
Oct 28, 2025
false 0001730430
0001730430
2025-10-28 2025-10-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 28, 2025
Kiniksa Pharmaceuticals International, plc
(Exact name of Registrant as Specified in Its Charter)
England and Wales
001-730430
98-1795578
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
23 Old Bond Street, Floor 3
London, W1S 4PZ
England, United Kingdom
(Address of principal executive offices, including zip code)
(781) 431-9100
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which
registered
Class A Ordinary Shares, $0.000273235 nominal value
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On October 28, 2025, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
99.1
Earnings Press Release issued by Kiniksa Pharmaceuticals International, plc, dated October 28, 2025
104
Cover Page Interactive Data File (embedded within the inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 28, 2025 By: /s/ Douglas Barry
Douglas Barry
Senior Vice President, Chief Legal Officer and Secretary
This page provides Kiniksa Pharmaceuticals Ltd. (KNSA) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on KNSA's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.